ERIS Lifesciences Ltd's Q3FY25 Quarter Results
- 05 Feb 2025
Result Summary
- ERIS Lifesciences Ltd reported a 1.9% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a growth of 49.2%.
- Its expenses for the quarter were down by 0.2% QoQ and up 64.3% YoY.
- The net profit decreased 9.8% QoQ and decreased 14.3% YoY.
- The earnings per share (EPS) of ERIS Lifesciences Ltd stood at 6.1 during Q3FY25.
Financial Statments for Q3FY25
| (₹ crores) | Q3FY25 | Q2FY25 | Q3FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 731.67 | 745.72 | 490.49 | -1.9% | 49.2% |
Total Expenses | 615.51 | 616.61 | 374.63 | -0.2% | 64.3% |
Profit Before Tax | 116.16 | 129.11 | 115.87 | -10.0% | 0.3% |
Tax | 29.23 | 32.76 | 14.41 | -10.8% | 102.8% |
Profit After Tax | 86.93 | 96.35 | 101.46 | -9.8% | -14.3% |
Earnings Per Share | 6.10 | 6.70 | 7.50 | -9.0% | -18.7% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
ERIS Lifesciences Ltd is a pharmaceutical company operating primarily in the Indian market. The company focuses on the manufacturing and marketing of branded pharmaceutical products in the chronic and acute therapeutic categories. ERIS Lifesciences is known for its extensive portfolio that includes drugs for cardiology, diabetes, gastroenterology, and other health conditions. The company has made significant strides in the Indian pharmaceutical industry, leveraging its strong sales and distribution network. Recent major developments concerning ERIS Lifesciences are not available from the data provided.
Revenue
During Q3FY25, ERIS Lifesciences Ltd reported a total income of ₹731.67 crores compared to ₹745.72 crores in Q2FY25, reflecting a quarter-over-quarter (QoQ) decrease of 1.9%. Compared to the same quarter in the previous year (Q3FY24), where total income was ₹490.49 crores, the company witnessed a year-over-year (YoY) growth of 49.2%. This significant YoY increase highlights the company's substantial revenue growth over the past year. The decrease in revenue on a quarterly basis indicates variability in income between quarters.
Profitability
For the third quarter of FY25, ERIS Lifesciences recorded a Profit Before Tax (PBT) of ₹116.16 crores, which decreased by 10.0% QoQ from ₹129.11 crores in Q2FY25. On a YoY basis, PBT showed a slight increase of 0.3% from ₹115.87 crores in Q3FY24. The Profit After Tax (PAT) for Q3FY25 was ₹86.93 crores, down by 9.8% QoQ from ₹96.35 crores in the preceding quarter, and a YoY decline of 14.3% from ₹101.46 crores in Q3FY24. The Earnings Per Share (EPS) followed a similar trend, decreasing to ₹6.10 in Q3FY25 from ₹6.70 in Q2FY25, registering a QoQ decline of 9.0% and a YoY decrease of 18.7% from ₹7.50 in Q3FY24.
Operating Metrics
The total expenses for ERIS Lifesciences in Q3FY25 were ₹615.51 crores, indicating a slight QoQ decrease of 0.2% from ₹616.61 crores in Q2FY25. However, on a YoY basis, expenses increased significantly by 64.3% from ₹374.63 crores in Q3FY24. The tax expense for Q3FY25 amounted to ₹29.23 crores, reflecting a QoQ decrease of 10.8% from ₹32.76 crores in Q2FY25, but a substantial YoY increase of 102.8% from ₹14.41 crores in Q3FY24. These metrics indicate fluctuations in operational costs and tax obligations over the quarterly and yearly periods.
